Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Wound-healing efficacy of PGI2 analogue confirmed in preclinical models

Aug. 13, 1998

Phase II study finds IL-2 fusion protein effective but toxic in patients with psoriasis

July 27, 1998

Antipsoriatic dihydrofolate reductase inhibitors available for licensing from BTG

July 22, 1998

Altana offer to license Solarase accepted by Hyal

July 21, 1998

Celgene cleared to market Thalomid in U.S.

July 20, 1998

First demonstration of efficacy for PDT in treating autoimmune disorders

July 17, 1998

Mylan announces copromotion agreement

July 15, 1998

Phase III trial of new foam formulation of clobetasol initiated

July 14, 1998

Dermatological agents in development at Galderma

July 10, 1998

Phase III study shows efficacy of becaplermin treatment for diabetic neuropathic ulcers

July 8, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...